Literature DB >> 2665353

New cholera vaccines.

J Holmgren1, J Clemens, D A Sack, A M Svennerholm.   

Abstract

Development of improved cholera vaccines has progressed rapidly in recent years. An oral killed vaccine, designed to evoke antibacterial as well as antitoxic intestinal immunity, has proved to be completely safe and to protect against cholera for at least 3 years. This vaccine also confers substantial though more short-lasting immunity against diarrhoea caused by enterotoxigenic Escherichia coli. Significant progress has also been made towards developing a live attenuated cholera vaccine using recombinant DNA techniques. The advent of effective oral cholera vaccines gives hope for improved control of cholera in the Third World.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2665353     DOI: 10.1016/0264-410x(89)90042-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Activation of cholera toxin-specific T cells in vitro.

Authors:  C O Elson; S Solomon
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

Review 2.  Oral delivery of vaccines. Formulation and clinical pharmacokinetic considerations.

Authors:  D T O'Hagan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

3.  Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity.

Authors:  W N Burnette; V L Mar; B W Platler; J D Schlotterbeck; M D McGinley; K S Stoney; M F Rohde; H R Kaslow
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

Review 4.  Optimal delivery of vaccines: clinical pharmacokinetic considerations.

Authors:  S Gizurarson
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

5.  Behavior of an Aeromonas hydrophila aroA live vaccine in water microcosms.

Authors:  José Vivas; Begoña Carracedo; Jorge Riaño; Blanca E Razquin; Pilar López-Fierro; Félix Acosta; Germán Naharro; Alberto J Villena
Journal:  Appl Environ Microbiol       Date:  2004-05       Impact factor: 4.792

6.  Immune response in the lungs following oral immunization with bacterial lysates of respiratory pathogens.

Authors:  C Ruedl; M Frühwirth; G Wick; H Wolf
Journal:  Clin Diagn Lab Immunol       Date:  1994-03

7.  Nontoxigenic Vibrio cholerae Challenge Strains for Evaluating Vaccine Efficacy and Inferring Mechanisms of Protection.

Authors:  Bolutife Fakoya; Karthik Hullahalli; Daniel H F Rubin; Deborah R Leitner; Roma Chilengi; David A Sack; Matthew K Waldor
Journal:  mBio       Date:  2022-04-07       Impact factor: 7.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.